scholarly journals Clozapine as an Effective Antipsychotic in Treatment Resistant Mania: Two Case Reports

2021 ◽  
Vol 9 (3) ◽  
pp. 107
Author(s):  
Mohamed Habib Aoun ◽  
Rabaa Jomli ◽  
Hend Jemli ◽  
Dorsaf Habbachi ◽  
Yosra Zgueb ◽  
...  
2016 ◽  
Author(s):  
Roy K. Esaki

Ketamine is an N-methyl-d-aspartate (NMDA) receptor antagonist that has been increasingly used in the management of treatment-resistant chronic pain conditions, particularly representing neuropathic involvement or central sensitization. Complex regional pain syndrome (CRPS) is a prototypical condition often treated with ketamine infusions. Although the analgesic benefits of ketamine as an opioid-sparing adjunct in the preoperative period have been well studied, the use of ketamine to mitigate chronic pain conditions remains largely anecdotal, composed largely of case reports and uncontrolled small studies. The limited evidence and published reports support the use of ketamine infusions as one aspect of a comprehensive, multimodal approach for CRPS. Although ketamine infusions are relatively safe when titrated appropriately, with minimal respiratory depression, side effects include sympathetic activation, unpleasant psychomimetic effects, lower urinary tract symptoms, and hepatic dysfunction. 


2019 ◽  
Vol 11 (2) ◽  
pp. 50-52
Author(s):  
Sanjeewani Fonseka ◽  
Y.M.D.M Bandara ◽  
Brabaharan Subhani

Abstract Introduction. Alopecia areata (AA) is an autoimmune disease-causing non-scarring alopecia. It is usually treated with immunosuppressive agents, to which some patients fail to respond adequately. Material and Methods. Three patients with AA refractory to standard therapy were treated with intra-dermal injection of autologous platelet rich plasma (PRP) every four weeks. Results. All three patients showed remarkable improvement after multiple sessions of PRP treatment. Conclusion. Autologous PRP is safe and effective in treatment-resistant forms of AA demonstrated in many case reports; therefore it deserves further study with randomized, placebo-controlled trials.


2003 ◽  
Vol 107 (5) ◽  
pp. 394-396 ◽  
Author(s):  
M. Jakovljević ◽  
M. Šagud ◽  
A. Mihaljević-Peleš

Author(s):  
Carl H. Miller ◽  
Martina Hummer ◽  
Roger Pycha ◽  
Wolfgang W. Fleischhacker

2011 ◽  
Vol 2011 ◽  
pp. 1-3
Author(s):  
Aleksandar Chanachev ◽  
Nicolas Ansermot ◽  
Séverine Crettol Wavre ◽  
Ute Nowotka ◽  
Maria-Eleni Stamatopoulou ◽  
...  

There exist many case reports and studies on the antipsychotic augmentation by aripirazole in partial responders to clozapine, the most seem to be finding a slight difference in the PANSS and CGI scores after the aripirazole addition. The results of our report are compatible with those of other studies but, we have found a considerable antianxiety action in both of the cases. The 5HT1A agonism of aripirazole could be hypothesized as mechanism contributing to this effect.


2015 ◽  
Vol 69 (8) ◽  
pp. 504-504
Author(s):  
Hirofumi Tesen ◽  
Hikaru Hori ◽  
Kiyokazu Atake ◽  
Hiroki Beppu ◽  
Jun Nakamura

1995 ◽  
Vol 5 (1) ◽  
pp. 69-79 ◽  
Author(s):  
JOVAN G. SIMEON ◽  
NORMAND J. CARREY ◽  
DOREEN M. WIGGINS ◽  
ROBERT P. MILIN ◽  
SHEIK N. HOSENBOCUS

Sign in / Sign up

Export Citation Format

Share Document